These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 15831831)

  • 1. Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies.
    Haley EC; Thompson JL; Levin B; Davis S; Lees KR; Pittman JG; DeRosa JT; Ordronneau P; Brown DL; Sacco RL;
    Stroke; 2005 May; 36(5):1006-10. PubMed ID: 15831831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial.
    Sacco RL; DeRosa JT; Haley EC; Levin B; Ordronneau P; Phillips SJ; Rundek T; Snipes RG; Thompson JL;
    JAMA; 2001 Apr; 285(13):1719-28. PubMed ID: 11277826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators.
    Lees KR; Asplund K; Carolei A; Davis SM; Diener HC; Kaste M; Orgogozo JM; Whitehead J
    Lancet; 2000 Jun; 355(9219):1949-54. PubMed ID: 10859040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the Glycine Antagonist Gavestinel on cerebral infarcts in acute stroke patients, a randomized placebo-controlled trial: The GAIN MRI Substudy.
    Warach S; Kaufman D; Chiu D; Devlin T; Luby M; Rashid A; Clayton L; Kaste M; Lees KR; Sacco R; Fisher M;
    Cerebrovasc Dis; 2006; 21(1-2):106-11. PubMed ID: 16340185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of blood pressure during the acute period of ischemic stroke on stroke outcome: a tertiary analysis of the GAIN International Trial.
    Aslanyan S; Fazekas F; Weir CJ; Horner S; Lees KR;
    Stroke; 2003 Oct; 34(10):2420-5. PubMed ID: 14500934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II studies of the glycine antagonist GV150526 in acute stroke : the North American experience. The North American Glycine Antagonist in Neuroprotection (GAIN) Investigators.
    Stroke; 2000 Feb; 31(2):358-65. PubMed ID: 10657406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health care resource use after acute stroke in the Glycine Antagonist in Neuroprotection (GAIN) Americas trial.
    Rundek T; Nielsen K; Phillips S; Johnston KC; Hux M; Watson D;
    Stroke; 2004 Jun; 35(6):1368-74. PubMed ID: 15118182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gavestinel produces no benefit for stroke patients, study finds.
    Clin Resour Manag; 2001 Nov; 2(11):173-5, 161. PubMed ID: 11727452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycine antagonist (GV150526) in acute stroke: a multicentre, double-blind placebo-controlled phase II trial.
    Lees KR; Lavelle JF; Cunha L; Diener HC; Sanders EA; Tack P; Wester P;
    Cerebrovasc Dis; 2001; 11(1):20-9. PubMed ID: 11173790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of a glycine site antagonist (gavestinel) following multiple dosing in patients with acute stroke.
    Hoke JF; Dyker AG; Barnaby RJ; Lees KR
    Eur J Clin Pharmacol; 2000; 55(11-12):867-72. PubMed ID: 10805066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poststroke neurological improvement within 7 days is associated with subsequent deterioration.
    Aslanyan S; Weir CJ; Johnston SC; Lees KR;
    Stroke; 2004 Sep; 35(9):2165-70. PubMed ID: 15243144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical diagnosis of lacunar stroke in the first 6 hours after symptom onset: analysis of data from the glycine antagonist in neuroprotection (GAIN) Americas trial.
    Phillips SJ; Dai D; Mitnitski A; Gubitz GJ; Johnston KC; Koroshetz WJ; Furie KL; Black S; Heiselman DE;
    Stroke; 2007 Oct; 38(10):2706-11. PubMed ID: 17717313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health care resource use and stroke outcome. Multinational comparisons within the GAIN International trial.
    Asplund K; Ashburner S; Cargill K; Hux M; Lees K; Drummond M;
    Int J Technol Assess Health Care; 2003; 19(2):267-77. PubMed ID: 12862185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials.
    Diener HC; Lees KR; Lyden P; Grotta J; Davalos A; Davis SM; Shuaib A; Ashwood T; Wasiewski W; Alderfer V; Hårdemark HG; Rodichok L;
    Stroke; 2008 Jun; 39(6):1751-8. PubMed ID: 18369171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How a sequential design would have affected the GAIN International Study of gavestinel in stroke.
    Bolland K; Weeks A; Whitehead J; Lees KR;
    Cerebrovasc Dis; 2004; 17(2-3):111-7. PubMed ID: 14707409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT Trial.
    Lyden PD; Shuaib A; Lees KR; Davalos A; Davis SM; Diener HC; Grotta JC; Ashwood TJ; Hardemark HG; Svensson HH; Rodichok L; Wasiewski WW; Ahlberg G;
    Stroke; 2007 Aug; 38(8):2262-9. PubMed ID: 17569876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The spot sign and tranexamic acid on preventing ICH growth--AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial.
    Meretoja A; Churilov L; Campbell BC; Aviv RI; Yassi N; Barras C; Mitchell P; Yan B; Nandurkar H; Bladin C; Wijeratne T; Spratt NJ; Jannes J; Sturm J; Rupasinghe J; Zavala J; Lee A; Kleinig T; Markus R; Delcourt C; Mahant N; Parsons MW; Levi C; Anderson CS; Donnan GA; Davis SM
    Int J Stroke; 2014 Jun; 9(4):519-24. PubMed ID: 23981692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood pressure variability on antihypertensive therapy in acute intracerebral hemorrhage: the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-intracerebral hemorrhage study.
    Tanaka E; Koga M; Kobayashi J; Kario K; Kamiyama K; Furui E; Shiokawa Y; Hasegawa Y; Okuda S; Todo K; Kimura K; Okada Y; Okata T; Arihiro S; Sato S; Yamagami H; Nagatsuka K; Minematsu K; Toyoda K
    Stroke; 2014 Aug; 45(8):2275-9. PubMed ID: 24968929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gavestinel. GV 150526, GV 150526A.
    Drugs R D; 1999 Jan; 1(1):23-4. PubMed ID: 10565975
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.